---
title: "Immix Biopharma, Inc. (IMMX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/IMMX.US.md"
symbol: "IMMX.US"
name: "Immix Biopharma, Inc."
industry: "Biotechnology"
---

# Immix Biopharma, Inc. (IMMX.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.immixbio.com](https://www.immixbio.com) |

## Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloido...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -16.47 | 493/605 | - | - | - |
| PB | 46.96 | 434/605 | 26.12 | 13.14 | 4.08 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-09T05:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 67% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.33 |
| Highest Target | 14.00 |
| Lowest Target | 7.20 |

## References

- [Company Overview](https://longbridge.com/en/quote/IMMX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/IMMX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/IMMX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.